000911484 001__ 911484
000911484 005__ 20230123101839.0
000911484 037__ $$aFZJ-2022-04753
000911484 1001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b0$$ufzj
000911484 245__ $$aPET and SPECT Imaging of Neurodegenerative Diseases
000911484 260__ $$aAmsterdam$$bElsevier$$c2021
000911484 29510 $$aMolecular Imaging: Principles and Practice
000911484 300__ $$a1309-1334
000911484 3367_ $$2ORCID$$aBOOK_CHAPTER
000911484 3367_ $$07$$2EndNote$$aBook Section
000911484 3367_ $$2DRIVER$$abookPart
000911484 3367_ $$2BibTeX$$aINBOOK
000911484 3367_ $$2DataCite$$aOutput Types/Book chapter
000911484 3367_ $$0PUB:(DE-HGF)7$$2PUB:(DE-HGF)$$aContribution to a book$$bcontb$$mcontb$$s1668669151_29672
000911484 500__ $$a 
000911484 520__ $$aToday, a number of complementary molecular imaging methods are at our disposal, which can make a relevant contribution to early diagnosis, differential diagnosis, disease monitoring, and follow-up of neurodegenerative diseases. This includes long-established FDG-PET which provides valuable information on location and extent of pathology and has demonstrated great value for early diagnosis, short-term prognosis, and for differential diagnosis of various disorders on the basis of the endophenotype of disease. Imaging of the dopaminergic system has proven value in the workup of movement disorders. More recently introduced, amyloid-PET for the first time allows in vivo diagnostic assessment of a molecular neuropathology, most valuable for verification or exclusion of Alzheimer disease (AD), independent of the symptomatic appearance. Finally, new tracers for tau-PET imaging may allow the assessment of location, extent, and specific type of pathology, which may hold great value for early and differential diagnosis of neurodegeneration in the future.
000911484 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000911484 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x1
000911484 7001_ $$0P:(DE-HGF)0$$aBischof, Gérard$$b1
000911484 7001_ $$0P:(DE-HGF)0$$aGiehl, Kathrin$$b2
000911484 7001_ $$0P:(DE-HGF)0$$aEimeren, Thilo van$$b3
000911484 8564_ $$uhttps://www.researchgate.net/publication/354825733_PET_and_SPECT_Imaging_of_Neurodegenerative_Diseases
000911484 909CO $$ooai:juser.fz-juelich.de:911484$$pVDB
000911484 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b0$$kFZJ
000911484 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000911484 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
000911484 9141_ $$y2022
000911484 920__ $$lyes
000911484 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000911484 980__ $$acontb
000911484 980__ $$aVDB
000911484 980__ $$aI:(DE-Juel1)INM-2-20090406
000911484 980__ $$aUNRESTRICTED